From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies (Q34321820)

1 August 2017

1 reference

title

From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies (English)

1 reference

1 August 2017

Isaacs JD

1

1 reference

1 August 2017

language of work or name

1 reference

1 July 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

40

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

724-738

1 reference

Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Induction of classical transplantation tolerance in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Induction of tolerance in peripheral T cells with monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

T-cell regeneration: all repertoires are not created equal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Short term immunosuppressive therapy and long-term immunoregulation: promises and problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Induction of tolerance by monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Tolerance to rat monoclonal antibodies. Implications for serotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.7.724

10.1093/RHEUMATOLOGY/40.7.724

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference